Profile data is unavailable for this security.
About the company
Alembic Pharmaceuticals Limited is an India-based diversified pharmaceutical company. The Company is engaged in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Labs LLC and others.
- Revenue in INR (TTM)63.57bn
- Net income in INR6.47bn
- Incorporated2010
- Employees14.86k
- LocationAlembic Pharmaceuticals LtdAlembic RoadVADODARA 390003IndiaIND
- Phone+91 2 656637000
- Fax+91 2 652281508
- Websitehttps://alembicpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 138.27bn | 3.07k | 78.24 | 6.08 | 37.20 | 3.14 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Sanofi India Ltd | 21.92bn | 3.60bn | 139.95bn | 2.17k | 38.86 | -- | 35.22 | 6.38 | 156.36 | 199.60 | 951.86 | -- | -- | -- | -- | 10,083,720.00 | -- | 22.42 | -- | 30.21 | 53.94 | 55.52 | 16.43 | 21.03 | -- | 348.40 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Marksans Pharma Ltd | 23.79bn | 3.47bn | 140.10bn | 2.00k | 40.35 | 6.14 | 32.55 | 5.89 | 7.66 | 7.66 | 52.53 | 50.34 | 0.9105 | 1.65 | 4.75 | 11,893,400.00 | 13.30 | 14.62 | 15.78 | 18.52 | 55.32 | 50.52 | 14.61 | 14.03 | 2.97 | 31.25 | 0.0792 | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Caplin Point Laboratories Ltd | 18.31bn | 4.94bn | 147.68bn | 859.00 | 30.02 | 5.81 | 26.38 | 8.07 | 64.73 | 64.73 | 240.10 | 334.54 | 0.6861 | 2.28 | 3.40 | 21,312,920.00 | 18.62 | 19.83 | 21.36 | 22.82 | 58.72 | 53.38 | 27.14 | 25.39 | 5.07 | 932.86 | 0.0009 | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Astrazeneca Pharma India Ltd | 14.85bn | 819.20m | 157.64bn | 940.00 | 192.45 | 23.20 | 153.62 | 10.62 | 32.76 | 32.76 | 593.93 | 271.74 | 1.27 | 2.52 | 10.63 | 15,792,680.00 | 6.99 | 11.78 | 11.44 | 19.62 | 44.88 | 54.64 | 5.52 | 10.27 | 1.44 | 134.82 | 0.0246 | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 179.04bn | 995.00 | 30.24 | 3.01 | 18.52 | 2.59 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 186.04bn | 3.08k | 53.45 | 6.71 | 29.87 | 7.45 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Neuland Laboratories Ltd. | 15.28bn | 2.80bn | 189.47bn | 1.65k | 67.75 | 13.65 | 55.14 | 12.40 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Wockhardt Ltd | 29.49bn | -2.88bn | 190.86bn | 2.39k | -- | 5.31 | -- | 6.47 | -19.85 | -19.85 | 201.29 | 221.32 | 0.393 | 1.87 | 4.19 | 12,318,300.00 | -3.93 | -4.56 | -6.33 | -8.29 | 59.10 | 55.26 | -10.00 | -12.70 | 0.5677 | 0.247 | 0.3869 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Alembic Pharmaceuticals Ltd | 63.57bn | 6.47bn | 204.00bn | 14.86k | 31.56 | 4.17 | 22.06 | 3.21 | 32.88 | 32.88 | 323.14 | 248.68 | 0.929 | 0.9366 | 5.43 | 4,278,678.00 | 9.45 | 10.72 | 13.32 | 14.25 | 73.84 | 65.98 | 10.17 | 12.47 | 0.8057 | 12.62 | 0.1791 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Concord Biotech Ltd | 10.86bn | 3.28bn | 208.31bn | 1.38k | 53.76 | 13.10 | 54.58 | 19.19 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Pfizer Ltd | 22.38bn | 6.18bn | 234.75bn | 1.72k | 37.99 | 6.26 | 34.58 | 10.49 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Emcure Pharmaceuticals Ltd | 72.56bn | 5.67bn | 242.76bn | 11.15k | 42.27 | 5.89 | 25.28 | 3.35 | 30.37 | 30.37 | 389.63 | 217.79 | 0.978 | 1.80 | 3.96 | 6,510,068.00 | 8.02 | 7.14 | 13.55 | 13.93 | 61.11 | 59.29 | 8.20 | 7.81 | 0.9549 | 5.25 | 0.2165 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Natco Pharma Ltd. | 45.61bn | 19.45bn | 246.23bn | 4.02k | 12.66 | 3.44 | 11.54 | 5.40 | 108.58 | 108.58 | 254.65 | 399.19 | 0.6291 | 0.8928 | 3.57 | 11,356,080.00 | 26.82 | 12.33 | 30.85 | 14.25 | 85.47 | 73.05 | 42.63 | 25.16 | 4.19 | 108.70 | 0.0283 | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
| Laurus Labs Ltd | 50.53bn | 1.31bn | 263.73bn | 6.01k | 201.06 | 6.38 | 48.37 | 5.22 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| J B Chemicals and Pharmaceuticals Ltd | 37.11bn | 6.11bn | 264.35bn | 5.31k | 44.27 | 8.23 | 34.40 | 7.12 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Data as of Nov 22 2024. Currency figures normalised to Alembic Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
14.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 8.50m | 4.33% |
| DSP Asset Managers Pvt. Ltd.as of 31 Oct 2024 | 8.00m | 4.07% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 2024 | 3.72m | 1.89% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.81m | 0.92% |
| Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 1.45m | 0.74% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 1.19m | 0.61% |
| Edelweiss Asset Management Ltd.as of 31 Oct 2024 | 1.12m | 0.57% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 755.96k | 0.39% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 748.62k | 0.38% |
| Baroda BNP Paribas Asset Management India Pvt Ltd.as of 31 Oct 2024 | 482.98k | 0.25% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
